Determinants of the blood pressure response to the first dose of ACE inhibitor in mild to moderate congestive heart failure
- 1 June 1998
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 45 (6) , 559-566
- https://doi.org/10.1046/j.1365-2125.1998.00728.x
Abstract
Aims To investigate the relationship in patients with heart failure between BP response to the first dose of ACE inhibitor and (1) plasma drug concentration and (2) baseline clinical and laboratory variables. Methods We studied individual placebo‐corrected BP responses to initiation of treatment with one of a number ACE inhibitor preparations in 132 patients with mild to moderate CHF. Various pharmacokinetic/pharmacodynamic models were compared. We assessed the strength of association between baseline physiological and laboratory variables and the BP response as assessed directly from the AUC(0,10 h) and indirectly from the slope of the PK/PD relationship. Predictive models for response variables were developing using regression analysis. Results BP response was primarily related to plasma drug concentration. The association between the fall in BP and baseline variables was weak. The strongest single predictor of BP response was baseline mean arterial pressure (r2=5.8%, P=0.02). The best combinations of predictor variables contained mean arterial pressure, plasma renin activity, creatinine concentration and age (r2=14.4%, P=0.37). When the choice of ACE inhibitor was added, the predictive power of the model increased (r2=23.6%, P Conclusions The first‐dose blood pressure response to ACE inhibition cannot be accurately predicted from baseline pathophysiological variables in patients with mild to moderate CHF. The choice of ACE inhibitor accounts for a small proportion of the variability in response but wide inter‐individual variability exists in the response to each treatment.Keywords
This publication has 29 references indexed in Scilit:
- Differing Early Blood Pressure and Renin-Angiotensin System Responses to the First Dose of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1996
- Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitalsThe American Journal of Cardiology, 1996
- A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1995
- Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild-to-moderate chronic congestive heart failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1994
- Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure.Heart, 1993
- Vascular tone in heart failure: the neuroendocrine-therapeutic interface.Heart, 1991
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Comparison of Captopril and Enalapril in Patients with Severe Chronic Heart FailureNew England Journal of Medicine, 1986
- Severe hypotension after first dose of enalapril in heart failure.BMJ, 1985
- Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 1978